Skip to content
sellModerate cluster of 3

Joseph Baroldi sold $610k of IONS

EVP, Chief Business Officer at IONIS PHARMACEUTICALS INC. 8,056 shares at an average of $75.75, traded Jan 16, 2026, filed Jan 20, 2026.

Warning score
40
Value
$610k
8,056 shares
Holdings after
4,772
-17% from before
From 52-week low
+199%
low $25.51, close $76.33
From 52-week high
-8%
high $83.17, as of Jan 16, 2026

Score components

  • Role
    Officer
    +15
  • Trade size
    $610k at market
    +20
  • Share of holdings sold
    Sold 17% of holdings
    +5
  • Cluster
    3 insiders selling within 14 days
    +15
  • Exercise and sell
    Shares came from an option exercise in the same filing
    -15

What happened after comparable sells

Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.

Price around the trade, and since

From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.

IONSOct 9, 2026 · close 45.28
Since filing Jan 20, 2026: -41.6%SPY +15.8% · excess -57.4%

Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™

Rows in this filing

Every transaction in Form 4 0000874015-26-000061, as filed. Open on EDGAR

DateTransactionSharesPriceValueHoldings afterFiled
Jan 15, 2026MOption exercise
Common Stock
+17,037$0.00$047,338Jan 20, 2026
Jan 16, 2026SOpen-market sale
Common Stock
-6,907$75.75$523k40,431Jan 20, 2026
Jan 15, 2026MOption exercise
Common Stockindirect: by Spouse
+2,850$0.00$05,921Jan 20, 2026
Jan 16, 2026SOpen-market sale
Common Stockindirect: by Spouse
-1,149$75.78$87k4,772Jan 20, 2026
Jan 15, 2026AGrant or award
Performance Restricted Stock Unitsderivative
+25,800$0.00$077,090Jan 20, 2026
Jan 15, 2026MOption exercise
Restricted Stock Unitderivative
-17,037$0.00$049,474Jan 20, 2026
Jan 15, 2026AGrant or award
Restricted Stock Unitderivative
+9,675$0.00$059,149Jan 20, 2026
Jan 15, 2026MOption exercise
Restricted Stock Unitderivativeindirect: by Spouse
-2,850$0.00$05,474Jan 20, 2026
Jan 15, 2026AGrant or award
Restricted Stock Unitderivativeindirect: by Spouse
+3,900$0.00$09,374Jan 20, 2026

Related signals

Other insiders at IONIS PHARMACEUTICALS INC and this insider’s other filings.

ScoreCompanyInsiderValueHoldingsFiled
33Weak
IONSsell 210b5-1
IONIS PHARMACEUTICALS INC
C Frank Bennett
EVP, Chief Scientific Officer
$6.7M
85,089 shares
-51%
11Weak
IONSsell 210b5-1
IONIS PHARMACEUTICALS INC
Joseph Baroldi
EVP, Chief Business Officer
$531k
6,659 shares
-15%
40Moderate
IONSsell 310b5-1
IONIS PHARMACEUTICALS INC
C Frank Bennett
EVP, Chief Scientific Officer
$7.1M
85,089 shares
-85%
48Moderate
IONSsell 3
IONIS PHARMACEUTICALS INC
C Frank Bennett
EVP, Chief Scientific Officer
$488k
5,885 shares
-6%
52Moderate
IONSsell 3
IONIS PHARMACEUTICALS INC
Joseph Baroldi
EVP, Chief Business Officer
$439k
5,296 shares
-10%
48Moderate
IONSsell 3
IONIS PHARMACEUTICALS INC
Brian Birchler
EVP, Corp and Development Ops
$513k
6,179 shares
-9%
35Weak
IONSsell 3
IONIS PHARMACEUTICALS INC
C Frank Bennett
EVP, Chief Scientific Officer
$675k
8,977 shares
-9%
40Moderate
IONSsell 3
IONIS PHARMACEUTICALS INC
Brian Birchler
EVP, Corp and Development Ops
$637k
8,480 shares
-12%
45Moderate
IONSsell 410b5-1
IONIS PHARMACEUTICALS INC
Joseph H Wender
director
$2.3M
28,000 shares
-44%
30Weak
IONSsell 410b5-1
IONIS PHARMACEUTICALS INC
Shannon L. Devers
EVP, Chief Human Resources Ofc
$1.4M
16,777 shares
-49%

Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.

Joseph Baroldi sold $610k of IONS | InsiderTell